Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because that oh-too-familiar routine of meetings, deadlines, and the like has returned with a vengeance.
You knew this would happen, yes? To cope, we are relying, as always, on cups of stimulation.
Our choice today is laced with traces of cocoa. Feel free to join us.
Remember, no prescription is required. Meanwhile, here are some tidbits to help you along.
Best of luck accomplishing your goals today and, of course, do keep in touch. … In February, a small biotech company called Kezar Life Sciences reached a breakthrough with the U.S.
Food and Drug Administration, agreeing to a plan for a clinical trial it hoped could lead to the approval of its treatment for a rare, debilitating liver disease called autoimmune hepatitis. The problem: The agreement came four months too late, STAT explains.
The meeting to discuss trial design, a critical step in the drug development process, had been scheduled for last October. But the FDA abruptly canceled it without explanation.
STAT News published a clinical update in Research Highlights on 06 Apr 2026.
The item focuses on STAT+: Pharmalittle: We’re reading about an FDA delay forcing a biotech to close, a Neurocrine deal, and more.
Review the original article for the full source wording and details.